10/2/2017 11:39:11 AM - Consolidating near multi-year highs following a streak of gains marked by above average volume. Noted with caution in prior mid-day reports - "Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14."
9/28/2017 12:31:21 PM - Rebounding toward multi-year highs today while tallying a 5th consecutive gain with ever-increasing volume. Noted with caution in prior mid-day reports - "Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14."
9/14/2017 1:07:03 PM - Rebounding toward multi-year highs. Noted with caution in prior mid-day reports - "Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14."
9/13/2017 1:52:18 PM - Rebounding toward multi-year highs. Noted with caution in prior mid-day reports - "Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14."
9/11/2017 12:36:58 PM - Rebounding toward multi-year highs, it hopped above its 50 DMA line with a gap up gain when last noted with caution in the 9/06/17 mid-day report - "Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14."
9/6/2017 1:13:43 PM - Rebounding toward multi-year highs, it hopped above its 50 DMA line with today's gap up gain. Quarterly earnings increases through Jun '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14.
6/28/2017 12:27:45 PM - Retreating from new 52-week and multi-year highs, slumping toward its 50 DMA line ($21.30) which recently acted as support. Quarterly earnings increases through Mar '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14.
5/24/2017 12:31:59 PM - Consolidating near 52-week and multi-year highs. Quarterly earnings increases through Mar '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14.
5/18/2017 12:35:18 PM - Consolidating near 52-week and multi-year highs. Quarterly earnings increases through Mar '17 have been below the +25% minimum guideline (C criteria). It was dropped from the Featured Stocks list on 7/31/14.
5/15/2017 12:12:35 PM - Consolidating near 52-week and multi-year highs. Quarterly earnings increases through Mar '17 have been below the +25% minimum guideline (C criteria) It was dropped from the Featured Stocks list on 7/31/14.
7/31/2014 11:11:17 AM - Gapped down today for a considerable volume-driven loss violating its prior lows and undercutting its 200 DMA line triggering more worrisome technical sell signals. It will be dropped from the Featured Stocks list tonight.
7/29/2014 8:13:29 PM - G - Encountered resistance again today at its 50 DMA line. A rebound above that important short-term average is needed for its outlook to improve. Faces resistance due to overhead supply up through the $46 area. See the latest FSU analysis for more details and annotated graphs.
7/22/2014 7:16:10 PM - G - Encountered resistance at its 50 DMA line, and a rebound above that important short-term average is needed for its outlook to improve. A subsequent violation of its recent low ($39.86 on 7/10/14) would raise more serious concerns and trigger more worrisome sell signals. Faces resistance due to overhead supply up through the $46 area.
7/16/2014 7:55:00 PM - G - Encountered resistance at its 50 DMA line and slumped for another loss today with lighter volume. Faces resistance due to overhead supply up through the $46 area.
7/15/2014 4:24:41 PM - G - Encountered resistance at its 50 DMA line today and tallied a small loss with higher volume indicative of distributional pressure. Faces resistance due to overhead supply up through the $46 area.
7/9/2014 5:48:26 PM - G - Recently slumped below its 50 DMA line with damaging losses. A rebound above the 50 DMA line is needed to help its outlook improve. See the latest FSU analysis for more details and new annotated graphs.
7/8/2014 6:25:17 PM - G - Slumped further below its 50 DMA line with today's 4th consecutive loss on higher volume. Disciplined investors always limit losses by selling any stock that falls more than -7% from their purchase price.
7/7/2014 4:26:22 PM - G - Violated its 50 DMA line with a damaging loss on higher (near average) volume triggering a technical sell signal and its color code is changed to green. Disciplined investors always limit losses by selling any stock that falls more than -7% from their purchase price.
7/3/2014 2:51:05 PM - Y - Volume totals have been cooling while consolidating above its 50 DMA line. Subsequent deterioration below its 50 DMA line would raise more serious concerns. Disciplined investors always limit losses by selling any stock that falls more than -7% from their purchase price. Keep in mind that any stock which is sold can be bought again later if strength returns.
6/27/2014 5:06:01 PM - Y - Halted its slide today with a small gain on light volume. Subsequent deterioration below its 50 DMA line would raise more serious concerns. Disciplined investors always limit losses by selling any stock that falls more than -7% from their purchase price. Keep in mind that any stock which is sold can be bought again later if strength returns.
6/23/2014 12:25:10 PM - Y - Color code is changed to yellow again as it found prompt support and rebounded quickly after undercutting prior highs near $43 and briefly violating its 50 DMA line with above average volume behind today's considerable early loss. Disciplined investors always limit losses by selling any stock that falls more than -7% from their purchase price. Keep in mind that any stock which is sold can be bought again later if strength returns.
6/23/2014 10:33:58 AM - G - Color code is changed to green as damaging losses have raised concerns. It undercut prior highs near $43 and violated its 50 DMA line with above average volume behind today's considerable early loss. Only a prompt rebound above its 50 DMA line ($41.78) would help its outlook.
6/17/2014 5:53:44 PM - Y - Volume totals have been cooling while consolidating below its "max buy" level following technical breakout. Prior highs near $43 area define near-term support to watch on pullbacks. See the latest FSU analysis for more details and new annotated graphs.
6/13/2014 5:59:46 PM - Y - Color code is changed to yellow after a 4th consecutive loss today on lighter volume led to a close below its "max buy" level. Prior highs near $43 area define near-term support to watch on pullbacks.
6/9/2014 6:57:47 PM - G - Color code is changed to green after finishing near the session high and above its "max buy" level with today's 5th consecutive gain on above average and ever-increasing volume. Prior highs near $43 area define near-term support to watch on pullbacks.
6/9/2014 12:33:22 PM - Y - Hit another new 52-week high today and traded above its "max buy" level. Triggered a technical buy signal on the prior session with a considerable volume-driven gain. Paid a Special Dividend on 6/05/14. Prior highs near $43 area define near-term support to watch on pullbacks.
6/6/2014 3:56:46 PM - Y - Triggering a technical buy signal today while hitting a new 52-week high with a 4th consecutive volume-driven gain. Paid a Special Dividend on 6/05/14. Prior highs near $43 area define near-term support to watch on pullbacks.
6/6/2014 2:33:56 PM - Y - Gains above its pivot point should be backed by at least +40% above average volume to trigger a proper technical buy signal. Hitting a new 52-week high with today's 4th consecutive volume-driven gain. Paid a Special Dividend on 6/05/14.
6/5/2014 12:45:51 PM - Y - Found support at its 50 DMA line and it is challenging its 52-week high while on track for a 3rd consecutive volume-driven gain. Paid a Special Dividend today. A gain above its pivot point backed by at least +40% above average volume may trigger a technical buy signal.
6/4/2014 12:27:33 PM - Y - Found support at its 50 DMA line and it is perched within close striking distance of its 52-week high today while on track for a 2nd consecutive volume-driven gain. A gain above its pivot point backed by at least +40% above average volume may trigger a technical buy signal.
6/3/2014 5:37:55 PM - Y - Finding support at its 50 DMA line after enduring distributional pressure. This Spanish firm from the Medical- Ethical Drugs industry needs subsequent volume-driven gains for new highs to trigger a technical buy signal. See the latest FSU analysis for more details and new annotated graphs.
6/3/2014 12:30:54 PM - Y - Finding support at its 50 DMA line after enduring distributional pressure. This Spanish firm from the Medical- Ethical Drugs industry needs subsequent volume-driven gains for new highs to trigger a technical buy signal.
6/2/2014 12:22:09 PM - Y - Pulling back today with higher volume and it has been encountering resistance recently near prior highs. This Spanish firm from the Medical- Ethical Drugs industry needs subsequent volume-driven gains for new highs to trigger a technical buy signal.
5/28/2014 6:14:10 PM - Y - Pulled back today with slightly higher volume and it has been encountering resistance at prior highs. This Spanish firm from the Medical- Ethical Drugs industry needs subsequent volume-driven gains for new highs to trigger a technical buy signal.
5/22/2014 9:23:39 PM - Y - Pulled back again today with lighter. Encountered resistance at prior highs. This Spanish firm from the Medical- Ethical Drugs industry needs subsequent volume-driven gains for new highs to trigger a technical buy signal.
5/19/2014 6:28:14 PM - Y - Tallied a solid gain today with above average volume, approaching the pivot point. This Spanish firm from the Medical- Ethical Drugs industry has little resistance remaining due to overhead supply. Subsequent volume-driven gains for new highs are needed to trigger a technical buy signal.
5/19/2014 12:23:51 PM - Y - Consolidating above its 50 DMA line with above average volume behind today's gain. Highlighted in yellow with pivot point cited based on its 3/11/14 high plus 10 cents in the 5/15/14 mid-day report (read here). This Spanish firm from the Medical- Ethical Drugs industry has little resistance remaining due to overhead supply. Subsequent volume-driven gains for new highs are needed to trigger a technical buy signal. Reported earnings +34% on +25% sales revenues for the Mar '14 quarter, marking its 4th consecutive quarter with earnings above the +25% minimum guideline (C criteria). See the latest FSU analysis for more details and annotated graphs.
5/16/2014 12:20:33 PM - Y - Consolidating near its 50 DMA line today, pulling back for a 2nd consecutive session with above average volume, indicating distributional pressure. Highlighted in yellow with pivot point cited based on its 3/11/14 high plus 10 cents in the 5/15/14 mid-day report (read here). This Spanish firm from the Medical- Ethical Drugs industry has little resistance remaining due to overhead supply. Subsequent volume-driven gains for new highs are needed to trigger a technical buy signal. Reported earnings +34% on +25% sales revenues for the Mar '14 quarter, marking its 4th consecutive quarter with earnings above the +25% minimum guideline (C criteria). See the latest FSU analysis for more details and annotated graphs.
5/15/2014 5:52:49 PM - Y - Highlighted in yellow with pivot point cited based on its 3/11/14 high plus 10 cents in the earlier mid-day report (read here). This Spanish firm from the Medical- Ethical Drugs industry is consolidating near its 50 DMA line with little resistance remaining due to overhead supply. Subsequent volume-driven gains for new highs are needed to trigger a technical buy signal. Reported earnings +34% on +25% sales revenues for the Mar '14 quarter, marking its 4th consecutive quarter with earnings above the +25% minimum guideline (C criteria). See the latest FSU analysis for more details and annotated graphs.
5/15/2014 12:37:31 PM - Y - Color code is changed to yellow with pivot point cited based on its 3/11/14 high plus 10 cents. This Spanish firm from the Medical- Ethical Drugs industry is consolidating near its 50 DMA line with little resistance remaining due to overhead supply. Subsequent volume-driven gains for new highs are needed to trigger a technical buy signal. Reported earnings +34% on +25% sales revenues for the Mar '14 quarter, marking its 4th consecutive quarter with earnings above the +25% minimum guideline (C criteria).
5/7/2014 12:27:09 PM - Consolidating near its 50 DMA line with little resistance remaining due to overhead supply. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
5/6/2014 12:29:19 PM - Pulling back near its 50 DMA line after gapping down today. Little resistance remains due to overhead supply. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
5/5/2014 12:11:48 PM - Rebounded above its 50 DMA line and little resistance remains due to overhead supply. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
5/2/2014 12:19:48 PM - Rebounded above its 50 DMA line this week and little resistance remains due to overhead supply. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
4/25/2014 12:18:04 PM - Encountered resistance at its 50 DMA line this week when rebounding from recent lows. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
4/11/2014 12:16:39 PM - Violated support at its 50 DMA line with recent losses. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
3/25/2014 1:59:34 PM - Finding support at its 50 DMA line today, an encouraging sign. Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
3/14/2014 12:15:46 PM - Reported earnings +39% on +10% sales revenues for the Dec '13 quarter, marking its 3rd consecutive quarter with earnings above the +25% minimum guideline (C criteria). Pulling back toward prior highs and its 50 DMA line defining near-term support to watch. Prior mid-day reports repeatedly cautioned members - "This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
3/4/2014 12:24:42 PM - Prior mid-day reports repeatedly cautioned members - "Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
2/19/2014 12:47:47 PM - Prior mid-day reports repeatedly cautioned members - "Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
2/18/2014 12:30:20 PM - Prior mid-day reports recently cautioned members - "Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
2/14/2014 12:17:39 PM - Prior mid-day reports recently cautioned members - "Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
2/13/2014 12:49:05 PM - The 2/10/14 mid-day report cautioned members - "Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par."
2/10/2014 12:59:28 PM - Perched near all-time highs with no resistance remaining due to overhead supply. This Spanish firm from the Medical- Ethical Drugs industry has shown good earnings increases in recent quarterly comparisons through Sep '13, however sales revenues growth has been sub par.